Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.53 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553303 | 1.00 | PDK2 (0.53) | PDK2LOXKMT2ANPC1RAB9A | |
| SCHEMBL3547540 | 0.86 | PDK2 (0.38) | PDK2 | |
| SCHEMBL3547543 | 0.86 | PDK2 (0.38) | PDK2 | |
| SCHEMBL3546501 | 0.84 | PDK2 (0.52) | PDK2LOXKMT2ANPC1RAB9A | |
| SCHEMBL3546499 | 0.84 | PDK2 (0.52) | PDK2LOXKMT2ANPC1RAB9A | |
| SCHEMBL3547392 | 0.79 | PDK2 (0.56) | PDK2LOX | |
| SCHEMBL3547391 | 0.79 | PDK2 (0.56) | PDK2LOX | |
| SCHEMBL13403430 | 0.77 | PDK2 (0.38) | PDK2 | |
| SCHEMBL13403416 | 0.76 | PDE5A (0.41) | PDK2 | |
| SCHEMBL7068414 | 0.76 | KMT2A (0.62) | PDK2LOXKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | PDK2 2445/4885LOX 2898/4885KMT2A 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.